Altimmune, Inc. (ALT) vs Phathom Pharmaceuticals, Inc. (PHAT)

Altimmune, Inc. and Phathom Pharmaceuticals, Inc. are both Biotechnology companies. Altimmune, Inc. and Phathom Pharmaceuticals, Inc. are of similar size ($593.3M and $572.8M). Altimmune, Inc. grew revenue faster over the last twelve months: 130.0% against 110.2%. Altimmune, Inc. has the higher net margin (0.00% vs −41.3%) and the lower return on invested capital (−34.3% vs 0.00%). Across the 16 metrics below, Phathom Pharmaceuticals, Inc. leads on 9 and Altimmune, Inc. on 7.

Valuation

Metric ALT PHAT Biotechnology median
P/E n/m n/m 7.88
P/S 12,336.04 2.55 11.47
P/B 1.20 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 6,007.86 2.49 10.73
Earnings yield (25.49%) (17.51%) (28.84%)
Free cash flow yield (13.53%) (6.03%) (23.03%)

Profitability

Metric ALT PHAT Biotechnology median
Gross margin 100.00% 82.92% 65.16%
Operating margin 0.00% (16.96%) 0.00%
Net margin 0.00% (41.34%) 0.00%
Free cash flow margin 0.00% (15.40%) 0.00%
Return on equity (28.87%) 26.42% (57.72%)
Return on assets (25.58%) (34.32%) (49.22%)
Return on invested capital (34.30%) 0.00% 0.00%

Growth

Metric ALT PHAT Biotechnology median
Revenue growth (TTM) 130.00% 110.16% 5.64%
EPS growth (last fiscal year) 25.37% 42.72% —
Revenue growth, 5-year CAGR (65.33%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALT PHAT Biotechnology median
Debt to equity 0.07 (0.48) 0.00
Current ratio 26.78 1.92 4.73
Net debt to EBITDA 2.49 (0.51) 0.96

Dividend

Metric ALT PHAT Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ALT PHAT Biotechnology median
Market cap 593.28m 572.78m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack